Skip to content

A parallel-serial DNA nanodevice enables multichannel decoding of the BACE1-AS1/BACE1 axis in Alzheimer’s disease

2026 · The Innovation Neurology · 0 citations · 30 references

Abstract

The accurate decoding of molecular interactions within disease-related signaling pathways remains a critical challenge for early and reliable diagnosis of Alzheimer’s disease (AD). While individual biomarkers such as BACE1 and its antisense transcript BACE1-AS1 have been widely studied, their coupled behavior within a functional axis proves difficult to interpret via single-output biosensing strategies. Here, we report a parallel–serial DNA nanodevice that translates the combined profile of the BACE1-AS1/BACE1 axis into multichannel fluorescence outputs. Built upon a hexagram DNA scaffold, the nanodevice generates distinct cleavage patterns in response to BACE1, BACE1-AS1, or their coexistence; these structural changes further convert into programmable downstream logic operations. Unlike conventional AND or OR logic gates that yield a single binary signal, this design combines parallel recognition with serial validation, generating three coordinated fluorescence readouts that reflect different pathway states. Results show that the device achieves limits of detection (LODs) of 0.16 nM and 0.56 nM for BACE1 and BACE1-AS1, respectively. Integration of multichannel outputs with machine learning (ML) models enables accurate discrimination of AD samples from healthy controls. Feature attribution analysis further reveals that BACE1-AS1 exerts a stronger influence on diagnostic classification than BACE1. By coupling DNA logic with multichannel signal cooperation, this work establishes a feasible strategy to convert molecular input signals into pathway-level characterizations and clinically interpretable readouts for AD detection.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.